azd4831
Small moleculeexperimental
Clinical trial activity
14 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02712372)
Timeline
Indications
Mechanism of action
- MyeloperoxidaseINHIBITOR
MPO inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](N)c1cc(Cl)ccc1Cn1c(=S)[nH]c(=O)c2[nH]ccc21- Mol. weight
- 334.83 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095218 ↗
Also known as
- azd4831
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05751759 | Phase 1 | Mar 20, 2023 | AstraZeneca |
| NCT05492877 | Phase 2 | Nov 14, 2022 | AstraZeneca |
| NCT05638737 | Phase 2 | Oct 26, 2022 | AstraZeneca |
| NCT05457270 | Phase 1 | Aug 11, 2022 | AstraZeneca, Parexel |
| NCT05236543 | Phase 1 | Feb 18, 2022 | AstraZeneca, Parexel |
| NCT05052710 | Phase 1 | Oct 5, 2021 | AstraZeneca |
| NCT04986202 | Phase 2/Phase 3 (Phase 3) | Jun 30, 2021 | AstraZeneca |
| NCT04949438 | Phase 1 | Jun 28, 2021 | AstraZeneca, Parexel |
| NCT04407091 | Phase 1 | Jun 8, 2020 | AstraZeneca, Quotient |
| NCT04232345 | Phase 1 | Jan 16, 2020 | AstraZeneca, Parexel |
| NCT03756285 | Phase 2 | Dec 11, 2018 | AstraZeneca |
| NCT03611153 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2018 | Mayo Clinic |
| NCT03136991 | Phase 1 | May 15, 2017 | AstraZeneca, California Clinical Trials, Parexel |
| NCT02712372 | Phase 1 | Jun 1, 2016 | AstraZeneca, Parexel |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 13 | 13 | 3 | 2016 |
| Parexel | For profit | 6 | 0 | 1 | 2016 |
| California Clinical Trials | For profit | 1 | 0 | 1 | 2017 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Quotient | For profit | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1